TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06029699

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula
Description: device are used for weaning patients after mechanical ventilation extubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive positive pressure ventilation
Description: device are used for weaning patients after mechanical ventilation extubation
Study: NCT04726943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy Applications
Description: RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
Study: NCT06030882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biologic Care Pathway
Description: Receiving care administered through a biologic care pathway.The central biologic intake nurse will touch base with the IBD program nurse navigator at preselected time points as per the pathway in order to coordinate the baseline pre- biologic work-up, clinical and biomarker assessments, and clinical assessments. Clinical management decisions will be informed by a combination of data points including clinical risk factors, TDM, fecal calprotectin concentrations, endoscopic and clinical disease activity indices as well as drug tolerance and adverse events. Within the care pathway, time- bound clinical and biomarker data will be provided to the treating clinician to help inform their clinical decisions.
Study: NCT05275309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exploration of optimal PEEP in supine and prone position
Description: 1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again.
Study: NCT05237947

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study: NCT05282433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Study: NCT05512273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery assisted osteotomy
Description: Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling osteotomy
Description: bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
Study: NCT06560905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: This is an imaging radionuclide tracer and is in chemical form. Up to 200 MBq. Route of administration is Intravenous.
Study: NCT06108830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine and remimazolam
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
Study: NCT04245384

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based dietetic treatment with video calls
Description: The dietitian meets the patient through video calls, no physical meetings
Study: NCT05740332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol hand sanitizer foam
Description: 1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)
Study: NCT04245384

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional dietetic treatment
Description: The dietitian meets the patient through physical meetings
Study: NCT05691010

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
Study: NCT05453435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
Study: NCT05815316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: (3S, 10S, 14S)-1-\[4-\[\[(2S)-4-carboxy-3-\[(2S)-4-carboxy-2-(6-\[18F\]fluoropyridin-3- amido)butanamido\]butanamido\]methyl\]phenyl\]-3- \[(naphtalen-2-yl)methyl\]-1,4,12-trioxo-2,5,11,13-tetraazahexadecane- 10,14,16-tricarboxilyc acid
Study: NCT05691010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Study: NCT05504551

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided superficial cervical plexus block
Description: SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
Study: NCT06067373

Intervention type: OTHER
Intervention: questionnaire
Description: After agreeing to participate, the patients receive a questionnaire in paper form.~This consists of a total of 12 higher-level self-compiled questions as well validated survey instruments. The free questions relate, among other things, to to the surgery postponement, the associated burden, complications occurred, Effects on the employment situation, as well as the current state. The following validated survey instruments are used in the questionnaire: the NCCN Distress Thermometer to record the mental stress, a Severity Symptom Scale to record the symptom burden and the PROMIS-10 for recording the health-related life quality.
Study: NCT04524130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: lidocaine will be given 1.5 mg/kg bolus at induction then 2mg/kg/hr until the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be given 0.35 mg/kg bolus at induction then 0.2 mg/kg/hr until the end of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline will be given with the same rate of lidocaine or ketamine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be given with the same rate of lidocaine or ketamine.
Study: NCT05504551

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guided superficial cervical plexus block
Description: SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
Study: NCT05827315

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 Cardiovascular Magnetic Resonance
Description: T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 Cardiovascular Magnetic Resonance
Description: T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 Cardiovascular Magnetic Resonance
Description: T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 Cardiovascular Magnetic Resonance
Description: T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: T1 Cardiovascular Magnetic Resonance
Description: T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterisation and coronary sinus blood sampling
Description: 10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
Study: NCT05500742

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 100 mcg tablets provided by Pharma Nord

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: 350 mg capsules provided by NOW Foods
Study: NCT06193382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCIT
Description: Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
Study: NCT05500742

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65 MD
Description: 100 unit capsules provided by TA Sciences
Study: NCT06113393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GRV thresholds
Description: Hold enteral feeding when GRV reaches 200 mL(current standard)
Study: NCT04750902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.24% Sodium Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% Arginine Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0% Arginine Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study: NCT05500742

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-1
Description: Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-2
Description: Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
Study: NCT06187805

Intervention type: DEVICE
Intervention: OSSIX Volumax
Description: OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
Study: NCT04877457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
Study: NCT04750902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.0% Arginine Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study: NCT03696563

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen administration - FreeO2
Description: The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard administration of oxygen flow
Description: The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
Study: NCT05339451

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Blood biomarkers in plasma and serum.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Blood biomarkers in plasma and serum.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Blood biomarkers in plasma and serum.
Study: NCT06134232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T Injection
Description: Single Infusion
Study: NCT00488605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone, Vinblastin, 6-mercaptopuroine
Description: Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin, Methotrexate, Vinblastine, Prednisone
Description: Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
Study: NCT05077046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic handwriting pen
Description: An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic handwriting pen
Description: An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
Study: NCT06390176

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG powder
Description: Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-containing tablets
Description: Starch preparations that look and taste like Lactobacillus rhamnosus GG powder

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
Study: NCT05606341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG1018
Description: 0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG1018
Description: 0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG1018
Description: 0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline injection supplied by the NYU Investigational Pharmacy.
Study: NCT06235489

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palfique Bulk Flow
Description: removal of caries in primary molars and placement of restorative materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palfique Bulk Flow
Description: removal of caries in primary molars and placement of restorative materials
Study: NCT04816071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: Dietary Supplement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential amino acids
Description: Dietary Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Control
Study: NCT05308771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VPC syringe
Description: Use of the visual pressure control syringe for epidural space detection
Study: NCT05876845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined pre-, pro-, and post-biotic supplement
Description: Participants will take 2 capsules daily with water, with their first meal of the day.
Study: NCT06386679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogenic amniotic fluid mesenchymal stem cell
Description: Intra-articular AFCC injection will be given for single knee for each patient in single dose, 20 million of AFCC in each dose
Study: NCT05353062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemostatic therapy
Description: Bipolar hemostatic forceps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy with hemoclip +/- injection of epinephrine solution
Description: Endoscopic therapy with hemoclip +/- injection of epinephrine solution
Study: NCT05418491

Intervention type: OTHER
Intervention: No intervention is used in the current study. Interventions were given in the original A.R.T. study
Description: The current study is a post-intervention study; interventions were given in the original A.R.T. study

Intervention type: OTHER
Intervention: No intervention is used in the current study. Interventions were given in the original A.R.T. study
Description: The current study is a post-intervention study; interventions were given in the original A.R.T. study

Intervention type: OTHER
Intervention: No intervention is used in the current study. Interventions were given in the original A.R.T. study
Description: The current study is a post-intervention study; interventions were given in the original A.R.T. study